# Antabio

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/antabio

- Industry: Biotechnology
- Headquarters: France
- Website: www.antabio.com
- Total disclosed funding: $43M
- Latest round: Series B (Dec 3, 2023)
- Investors on record: 9

## About

Based in France, Antabio SAS specializes in the development of innovative antibacterial therapies to combat drug-resistant infections, working primarily with healthcare providers to address critical global health challenges.Antabio SAS, founded in 2009 in France, focuses on creating antibacterial therapies. The company has secured a total of 12 funding deals, with the latest being a Series B round raising EUR 25 million on December 3, 2023, led by AMR Action Fund and supported by various investors including BNP Paribas Développement and the European Innovation Council. Helmuth van Es is the founder, who has a background in health-focused ventures, while Marc Lemonnier serves as the CEO.Antabio is focused on developing innovative antibacterial therapies aimed at combating drug-resistant infections, particularly those identified as critical priorities by the World Health Organization (WHO). The company's main product pipeline includes MEM-ANT3310, a Pseudomonas elastase inhibitor (PEi), designed to specifically target pathogens resistant to standard antibiotics. These products are intended for use in healthcare settings, addressing the urgent need for effective treatments against nosocomial infections and antibiotic-resistant strains. Antabio primarily serves hospitals and healthcare providers in regions significantly affected by antimicrobial resistance, including North America and Europe, where the prevalence of drug-resistant infections is particularly high.Antabio's revenue model revolves around partnerships with healthcare institutions and pharmaceutical companies for the development and commercialization of its antibacterial products. The company generated EUR 35,716.80 in revenue for the most recent year 2018, alongside an EBITDA of EUR -3,976,199.30. The transaction structure typically involves direct sales agreements and strategic partnerships that facilitate the integration of their therapies into clinical practice. Revenue may also be generated through research collaborations and licensing agreements with other biopharmaceutical firms interested in developing complementary treatments.In December 2023, Antabio SAS raised EUR 25 million in Series B funding, which will be utilized for the clinical trial of its antibiotic combination MEM-ANT3310. The company aims to expand its product offerings and develop new treatments to combat antimicrobial resistance. Plans for market expansion include targeting regions with high demand for effective antibacterial therapies, with particular focus on North America and Europe. The funding from the recent round will support the clinical development and commercialization efforts aimed at enhancing their presence in these critical markets.

## Funding rounds

- Series B, Dec 3, 2023, $27M — Turenne Groupe, Irdi Capital Investissement, European Innovation Council, BNP Paribas Developpement, AMR Action Fund
- Series A, Nov 29, 2021, $3.9M — Omnes Capital, IXO Private Equity, Galia Gestion, Irdi Capital Investissement, Sham Innovation Santé, BNP Paribas Developpement
- Series A, Oct 23, 2018, $5.9M — Omnes Capital, Galia Gestion, BNP Paribas Developpement
- Series A, Dec 13, 2017, $6M — IXO Private Equity, Galia Gestion, Irdi Capital Investissement

## Investors

- IXO Private Equity (https://capitalatlas.ai/funds/ixo-private-equity) — Series A
- Galia Gestion (https://capitalatlas.ai/funds/galia-gestion) — Series A
- Irdi Capital Investissement (https://capitalatlas.ai/funds/irdi-capital-investissement) — Series A, Series B
- Omnes Capital (https://capitalatlas.ai/funds/omnes-capital) — Series A
- BNP Paribas Developpement (https://capitalatlas.ai/funds/bnp-paribas-developpement) — Series A, Series B
- Sham Innovation Santé — Series A
- Turenne Groupe (https://capitalatlas.ai/funds/turenne-groupe) — Series B
- European Innovation Council (https://capitalatlas.ai/funds/european-innovation-council) — Series B
- AMR Action Fund (https://capitalatlas.ai/funds/amr-action-fund) — Series B